$19.74
00.00%
Pre-Market: 5:08 PM EDT
15 minutes delayed
Comments
Loading...
Evolent Health
EVHNYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Evolent Health (NYSE:EVH) Stock, Analyst Ratings, Price Targets, Forecasts
Evolent Health Inc has a consensus price target of $43.43 based on the ratings of 14 analysts. The high is $59 issued by Cowen & Co. on January 30, 2023. The low is $33 issued by Piper Sandler on November 4, 2022. The 3 most-recent analyst ratings were released by Canaccord Genuity, JMP Securities, and Citigroup on May 10, 2024, May 10, 2024, and April 22, 2024, respectively. With an average price target of $38.33 between Canaccord Genuity, JMP Securities, and Citigroup, there's an implied 94.19% upside for Evolent Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
JMP Securities
Citigroup
JP Morgan
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Evolent Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/10/2024 | Buy Now | 107.7% | Canaccord Genuity | Richard Close | $44 → $41 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 72.24% | JMP Securities | Constantine Davides | $38 → $34 | Maintains | Market Outperform | Get Alert |
| 04/22/2024 | Buy Now | 102.63% | Citigroup | Daniel Grosslight | → $40 | Initiates | → Buy | Get Alert |
| 03/28/2024 | Buy Now | 122.9% | Canaccord Genuity | Richard Close | $45 → $44 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 163.42% | JP Morgan | Anne Samuel | $53 → $52 | Maintains | Overweight | Get Alert |
| 03/01/2024 | Buy Now | 127.96% | Oppenheimer | Jeff Jones | → $45 | Initiates | → Outperform | Get Alert |
| 02/23/2024 | Buy Now | 92.5% | JMP Securities | Constantine Davides | $37 → $38 | Maintains | Market Outperform | Get Alert |
| 02/23/2024 | Buy Now | 127.96% | Canaccord Genuity | Richard Close | $47 → $45 | Maintains | Buy | Get Alert |
| 12/06/2023 | Buy Now | 87.44% | JMP Securities | Constantine Davides | → $37 | Initiates | → Market Outperform | Get Alert |
| 11/28/2023 | Buy Now | 112.77% | RBC Capital | Sean Dodge | $44 → $42 | Maintains | Outperform | Get Alert |
| 11/14/2023 | Buy Now | 72.24% | Truist Securities | Sandy Draper | $36 → $34 | Maintains | Hold | Get Alert |
| 10/16/2023 | Buy Now | 133.03% | UBS | Kevin Caliendo | → $46 | Initiates | → Buy | Get Alert |
| 08/14/2023 | Buy Now | 138.1% | Guggenheim | Sandy Draper | → $47 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 138.1% | Guggenheim | Sandy Draper | $50 → $47 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | 122.9% | RBC Capital | Sean Dodge | → $44 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 102.63% | Stephens & Co. | Jeff Garro | → $40 | Reiterates | → Overweight | Get Alert |
| 04/12/2023 | Buy Now | 102.63% | Stephens & Co. | Jeff Garro | → $40 | Initiates | → Overweight | Get Alert |
| 02/23/2023 | Buy Now | 122.9% | RBC Capital | Sean Dodge | → $44 | Reiterates | → Outperform | Get Alert |
| 01/30/2023 | Buy Now | 198.89% | Cowen & Co. | Charles Ryhee | $57 → $59 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | 188.75% | Cowen & Co. | Charles Ryhee | $52 → $57 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 67.17% | Piper Sandler | Jessica Tassan | $40 → $33 | Maintains | Overweight | Get Alert |
| 11/01/2022 | Buy Now | 67.17% | Truist Securities | Sandy Draper | → $33 | Initiates | → Hold | Get Alert |
| 10/12/2022 | Buy Now | 143.16% | Canaccord Genuity | Richard Close | $55 → $48 | Maintains | Buy | Get Alert |
| 10/12/2022 | Buy Now | 127.96% | BTIG | David Larsen | $55 → $45 | Maintains | Buy | Get Alert |
| 08/19/2022 | Buy Now | 163.42% | JP Morgan | Anne Samuel | $37 → $52 | Maintains | Overweight | Get Alert |
| 08/03/2022 | Buy Now | 122.9% | RBC Capital | Sean Dodge | $40 → $44 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 153.29% | BTIG | David Larsen | $45 → $50 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 102.63% | Piper Sandler | Jessica Tassan | $35 → $40 | Maintains | Overweight | Get Alert |
| 07/29/2022 | Buy Now | 102.63% | RBC Capital | Sean Dodge | → $40 | Initiates | → Outperform | Get Alert |
| 06/21/2022 | Buy Now | 153.29% | Cowen & Co. | Charles Rhyee | $48 → $50 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 127.96% | Canaccord Genuity | Richard Close | $40 → $45 | Maintains | Buy | Get Alert |
| 03/30/2022 | Buy Now | 117.83% | Guggenheim | Sandy Draper | → $43 | Initiates | → Buy | Get Alert |
| 03/25/2022 | Buy Now | 102.63% | BTIG | David Larsen | $35 → $40 | Maintains | Buy | Get Alert |
| 11/18/2021 | Buy Now | 87.44% | JP Morgan | Anne Samuel | — | Upgrade | Neutral → Overweight | Get Alert |
| 08/05/2021 | Buy Now | 36.78% | Canaccord Genuity | Richard Close | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Evolent Health (EVH) stock?
The latest price target for Evolent Health (NYSE:EVH) was reported by Canaccord Genuity on May 10, 2024. The analyst firm set a price target for $41.00 expecting EVH to rise to within 12 months (a possible 107.70% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evolent Health (EVH)?
The latest analyst rating for Evolent Health (NYSE:EVH) was provided by Canaccord Genuity, and Evolent Health maintained their buy rating.
When was the last upgrade for Evolent Health (EVH)?
The last upgrade for Evolent Health Inc happened on November 18, 2021 when JP Morgan raised their price target to $37. JP Morgan previously had a neutral for Evolent Health Inc.
When was the last downgrade for Evolent Health (EVH)?
There is no last downgrade for Evolent Health.
When is the next analyst rating going to be posted or updated for Evolent Health (EVH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evolent Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evolent Health was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.
Is the Analyst Rating Evolent Health (EVH) correct?
While ratings are subjective and will change, the latest Evolent Health (EVH) rating was a maintained with a price target of $44.00 to $41.00. The current price Evolent Health (EVH) is trading at is $19.74, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.